標(biāo)題: Titlebook: Chemotherapy for Leukemia; Novel Drugs and Trea Takanori Ueda Book 2017 Springer Nature Singapore Pte Ltd. 2017 Acute promyelocytic leukemi [打印本頁] 作者: FETID 時間: 2025-3-21 18:45
書目名稱Chemotherapy for Leukemia影響因子(影響力)
書目名稱Chemotherapy for Leukemia影響因子(影響力)學(xué)科排名
書目名稱Chemotherapy for Leukemia網(wǎng)絡(luò)公開度
書目名稱Chemotherapy for Leukemia網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Chemotherapy for Leukemia被引頻次
書目名稱Chemotherapy for Leukemia被引頻次學(xué)科排名
書目名稱Chemotherapy for Leukemia年度引用
書目名稱Chemotherapy for Leukemia年度引用學(xué)科排名
書目名稱Chemotherapy for Leukemia讀者反饋
書目名稱Chemotherapy for Leukemia讀者反饋學(xué)科排名
作者: Perineum 時間: 2025-3-21 21:25 作者: 有說服力 時間: 2025-3-22 01:20
Imatinib: Clinical Pharmacology and Therapeutic Resultsd with improved prognosis in several studies. Furthermore, approximately 40% of patients who exhibited sustained deep molecular response could maintain treatment-free remission after discontinuation of imatinib. Treatment-free remission is now considered to be a new goal of tyrosine kinase inhibitor作者: Malaise 時間: 2025-3-22 06:41
Rituximab and Alemtuzumab for Chronic Lymphocytic Leukemia: Basic Results and Pharmacokineticsimab resistance in the treatment of chronic lymphocytic leukemia (CLL). The characteristic toxicities of rituximab are infusion reactions, late-onset neutropenia, hepatitis B virus reactivation, and opportunistic infections..Alemtuzumab is a humanized anti-CD52 mAb and the first mAb to be approved f作者: 針葉類的樹 時間: 2025-3-22 12:35 作者: Generosity 時間: 2025-3-22 16:33 作者: Generosity 時間: 2025-3-22 18:08 作者: 刺耳 時間: 2025-3-23 01:10
Retinoic Acid, All-, Retinoic Acid (ATRA), and Tamibaroteney in both untreated APL patients and relapsed patients who have been treated with ATRA and chemotherapy. Retinoids are a model of the development of new molecular-targeted agents for other malignant tumors.作者: 種子 時間: 2025-3-23 04:05
Nelarabinetravenous (IV) infusion given over 2 h on days 1, 3, and 5 and repeated every 21 days. In pediatric patients, the recommended dose is 650 mg/m. IV given over 1 h for five consecutive days and repeated every 21 days. In a large phase II study conducted by the German Multicenter Study Group for Adult 作者: 挖掘 時間: 2025-3-23 08:13 作者: 溫和女人 時間: 2025-3-23 10:47
https://doi.org/10.1007/978-3-642-24070-6liferative signals. Although imatinib is an effective frontline therapy that has provided a remarkable success in the treatment of CML, the resistance to the inhibitor is still an obstacle. Quiescent leukemic stem cells are unresponsive to imatinib. BCR-ABL-dependent and BCR-ABL-independent mechanis作者: mastopexy 時間: 2025-3-23 14:38 作者: EWE 時間: 2025-3-23 18:13 作者: RAGE 時間: 2025-3-24 02:14
Harald Atmanspacher,Thomas Filkntional chemotherapy for patients with relapsed/refractory ALL showed better objective response. This review summarizes the clinical efficacy and safety of INO in the treatment of relapsed/refractory ALL, based on currently available data in the literature.作者: Blasphemy 時間: 2025-3-24 04:36 作者: 窩轉(zhuǎn)脊椎動物 時間: 2025-3-24 08:26 作者: 招待 時間: 2025-3-24 11:29
https://doi.org/10.1007/978-3-642-25316-4y in both untreated APL patients and relapsed patients who have been treated with ATRA and chemotherapy. Retinoids are a model of the development of new molecular-targeted agents for other malignant tumors.作者: 凹槽 時間: 2025-3-24 17:35 作者: obsolete 時間: 2025-3-24 20:32 作者: BARB 時間: 2025-3-25 01:28 作者: 削減 時間: 2025-3-25 07:09
Imatinib: Clinical Pharmacology and Therapeutic Resultsssion-free survival and overall survival associated with imatinib therapy (400 mg daily) have ranged between 83–94% and 83–97%, respectively. Imatinib is generally well tolerated, and adverse events are typically manageable. Current evidence does not support the extensive use of high-dose imatinib (作者: MURKY 時間: 2025-3-25 08:05
Dasatinib, Nilotinib, Bosutinib, Ponatinib, and Other TKIsce and intolerance to imatinib are frequently reported, particularly in patients with advanced-stage disease; this leads to around 30% of CML patients discontinuing imatinib treatment. Point mutations within the . kinase domain, which interfere with imatinib binding, are the most critical cause of i作者: 清澈 時間: 2025-3-25 13:40
Rituximab and Alemtuzumab for Chronic Lymphocytic Leukemia: Basic Results and Pharmacokineticsms of action of rituximab include antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and induction of apoptosis. The influences of CD20 expression level, circulating soluble CD20, Fcγ receptor (FcγR) polymorphisms, complement regulatory proteins, and C1qA-276 p作者: Obscure 時間: 2025-3-25 19:28 作者: 白楊魚 時間: 2025-3-25 23:17 作者: 自制 時間: 2025-3-26 02:54 作者: 增長 時間: 2025-3-26 07:57
FLT3 Inhibitorson is the most frequent genetic alteration in acute myeloid leukemia (AML) and is associated with poor prognosis in AML patients. Since high-dose chemotherapy including allogeneic hematopoietic stem cell transplantation cannot overcome a poor prognosis, development of FLT3 inhibitor is highly expect作者: 刺穿 時間: 2025-3-26 10:42
Retinoic Acid, All-, Retinoic Acid (ATRA), and Tamibaroteneete remission (CR) in patients with acute promyelocytic leukemia (APL). Although introduction of ATRA as a differentiating agent has been a major breakthrough in the treatment of APL, ATRA is currently recognized as a molecular-targeted therapy directed at the PML-RARα chimeric protein, which is gen作者: patriarch 時間: 2025-3-26 14:22 作者: 書法 時間: 2025-3-26 20:43 作者: 開花期女 時間: 2025-3-26 22:51
Nelarabineethoxylated to ara-G by adenosine deaminase in the blood. The ara-G is subsequently transported into cancer cells via nucleoside transporters. Inside the cells, ara-G is phosphorylated by either deoxycytidine kinase to cytosolic ara-G monophosphate or by deoxyguanosine kinase to mitochondrial ara-G 作者: 獎牌 時間: 2025-3-27 03:44 作者: Absenteeism 時間: 2025-3-27 07:27 作者: 真實的人 時間: 2025-3-27 09:42 作者: 晚間 時間: 2025-3-27 15:36 作者: averse 時間: 2025-3-27 21:51
Rituximab and Alemtuzumab for Chronic Lymphocytic Leukemia: Clinical Pharmacology and Therapeutic Remended for unfit patients with relevant comorbidities without . defects. Alemtuzumab has proven efficacy in patients with . defects and has become a therapeutic option for these patients, but its role in the management of B-CLL patients is hampered by its substantial toxicity.作者: arthroscopy 時間: 2025-3-28 01:04
The Molecular Basis of Arsenic Trioxide Treatment for Acute Promyelocytic Leukemia (APL)promyelocytic differentiation, leading ultimately to cell death of APL cells. Recent studies have shown that the combination of ATRA and ATO has synergistic effects in vitro and in vivo, and these findings have translated successfully to the clinic with great improved outcome for APL patients.作者: Exploit 時間: 2025-3-28 03:53 作者: 柔美流暢 時間: 2025-3-28 10:05
Two-Step Double Photoionization of MoleculesTherefore, a third-generation ABL TKI, ponatinib, was developed and shows good clinical efficacy against CML cells harboring the T315I mutation. Thus, treatments for CML are progressing rapidly, and further evolution is expected.作者: 費(fèi)解 時間: 2025-3-28 11:32
Dasatinib, Nilotinib, Bosutinib, Ponatinib, and Other TKIsTherefore, a third-generation ABL TKI, ponatinib, was developed and shows good clinical efficacy against CML cells harboring the T315I mutation. Thus, treatments for CML are progressing rapidly, and further evolution is expected.作者: incontinence 時間: 2025-3-28 14:39
Book 2017iveness of treatment for chronic myeloid leukemia and acute promyelocytic leukemia has been dramatically improved in recent years. This improvement has been made possible with the development of molecular targeted agents such as bcr-abl tyrosine kinase inhibitors and all-trans retinoic acid. The ant作者: paradigm 時間: 2025-3-28 19:43 作者: cogitate 時間: 2025-3-29 01:46
http://image.papertrans.cn/c/image/224970.jpg作者: 描繪 時間: 2025-3-29 04:07
https://doi.org/10.1007/978-981-10-3332-2Acute promyelocytic leukemia; Chronic myeloid leukemia; Molecular targeted agent; antimetabolite analog作者: neutralize 時間: 2025-3-29 09:57 作者: 勤勞 時間: 2025-3-29 15:28 作者: 包庇 時間: 2025-3-29 18:26
An Overview,There has been remarkable progress in chemotherapy for leukemia and related diseases, including promising studies that are still in progress. The contents consist of three parts:.In this chapter, an overview of these drugs presented in this book is briefly described.作者: Hirsutism 時間: 2025-3-29 21:10 作者: inundate 時間: 2025-3-30 02:06 作者: 震驚 時間: 2025-3-30 05:16 作者: elastic 時間: 2025-3-30 09:49 作者: 溺愛 時間: 2025-3-30 15:01
https://doi.org/10.1007/978-3-642-24440-7eatment strategy for B-CLL. The addition of anti-CD20 antibody to its management has remarkably improved the survival of B-CLL patients. Fludarabine, cyclophosphamide, and rituximab (FCR) is a standard treatment for physically fit patients without . defects, while bendamustine and rituximab (BR) is 作者: 意見一致 時間: 2025-3-30 17:56 作者: DEAF 時間: 2025-3-30 21:50
